Ferrer’s researchers seek to treat diseases and the symptoms associated with diseases. Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs.
Patients are enrolled in clinical studies that are consistent with the principles of the Declaration of Helsinki and its amendments as well as the laws, regulations, and provisions of those countries where people are enrolled*.
Find out more about our studies and how to enroll:
|ADORE||A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FNP122 (oral edaravone) in patients with amyotrophic lateral sclerosis.||in follow-up||more details|
|ADOREXT||A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with amyotrophic lateral sclerosis.||recruiting (rolling over of patients from the main study to the extension study||more details|
|AMDC 009-103||A cross-over, phase 1, open-label 2-arm study to investigate the relative bioavailability of FNP 150 (apomorphine Staccato®) compared with subcutaneous apomorphine in male or female participants, age 30–80 years old, with Parkinson’s disease.||recruiting||-|
|PAH Care||Assessment of clinical benefit, safety and patient-reported outcomes of the use of PAHcare™ Platform for routine care of patients with pulmonary arterial hypertension.||enrolled||-|
|AMDC 010-201||A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of FNP 010 (granisetron Staccato®) for the acute treatment of moderate to severe cyclic vomiting syndrome.||enrolled||more details|
* All products described on this page are investigational and have not been approved for any use by the European Medicines Agency (EMA), United States Food and Drug Administration (FDA) or any other health authority. The safety and efficacy of these investigational products have not been established.